The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment

被引:0
|
作者
Mehmet Aliustaoglu
Ahmet Bilici
Bala Basak Oven Ustaalioglu
Volkan Konya
Murat Gucun
Mesut Seker
Mahmut Gumus
机构
[1] Haydarpasa Numune Education and Research Hospital,Department of Medical Oncology
[2] Dr. Lütfi Kirdar Kartal Education and Research Hospital,Department of Medical Oncology
来源
Medical Oncology | 2010年 / 27卷
关键词
Neutrophil; Platelet; Lymphocyte; Platelet-lymphocyte ratio; Neutrophil–lymphocyte ratio; Gastric cancer;
D O I
暂无
中图分类号
学科分类号
摘要
We aimed to investigate the prognostic significance of neutrophil, lymphocyte, platelet, mean platelet value (MPV), platelet-lymphocyte ratio (PLR) and neutrophil–lymphocyte ratio (NLR) in patients with locally advanced gastric cancer (LAGC). One hundred sixty-eight patients with LAGC who had been followed-up between 2004 and 2008 were included in present study. The results of hematological (platelet, lymphocyte, neutrophil and MPV) and biochemical (uric acid and LDH) parameters were evaluated before treatment. NLR was divided into two groups as <2.56 and ≥2.57 and PLR was also divided into two groups as ≤160 and >160. Platelet counts and lymphocyte counts were also divided into two groups; ≤300.000/mm3 and >300.000/mm3, and <1,500/mm3 and ≥1,500/mm3, respectively. Results were evaluated with Kaplan–Meier and Long-rank tests. The mean age of patients at diagnosis was 60.1 ± 12.1 and 114 of patients (67.8%) were male. For 168 patients, 48 months overall survival (OS) rate was 45.2% and the median OS was 39 months (range 33–44). In patients whose PLR was less than 160 (n = 54), the median OS was 45 months (range 38–52) and also for cases whose PRL was greater than 160 (n = 114), the median OS was 27 months (range 22–32) (p = 0.006). While for fifty patients whose lymphocyte counts were less than 1,500, the median OS was 27 months (range 21–33), in cases with high lymphocyte counts (≥1,500) (n = 118), it was 41 months (range 35–48) (p = 0.03). The median OS was 41 (range 34–48) and 30 (range 23–37) months in two platelets groups, respectively (p = 0.24). However, in the patients whose NLR was less than 2.56 (n = 107), median OS was better than with cases whose NLR was greater than or equal to 2.56 (42 vs. 27 months). Routine peripheral blood counts may be useful prognostic factor for evaluating the accuracy of risk stratification in patients with radically resected gastric cancer Our results need to be confirmed by study including larger sample size in future.
引用
收藏
页码:1060 / 1065
页数:5
相关论文
共 50 条
  • [41] Verification of Pre-treatment NLR and PLR on the Prognosis of Patients with Locally Advanced Cervical Cancer
    Wang, D.
    Hou, X.
    Hu, K.
    Zhang, F. Q.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E498 - E498
  • [42] Prognosis and treatment regimens for patients with different lymph node statuses in locally advanced cervical cancer
    Guo, Wendi
    Li, Na
    Ren, Runling
    Hu, Yuanjing
    EJSO, 2024, 50 (11):
  • [43] Somatic pharmacogenomics in the treatment prognosis of locally advanced rectal cancer patients: a narrative review of the literature
    Milan, Noemi
    Navarria, Federico
    Cecchin, Erika
    De Mattia, Elena
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2024, 17 (08) : 683 - 719
  • [44] Improvement of QOL and Prognosis by Treatment of Superfine Dispersed Lentinan in Patients with Advanced Gastric Cancer
    Yoshino, Shigefumi
    Watanabe, Seiji
    Imano, Motohiro
    Suga, Tetsuya
    Nakazawa, Saburo
    Hazama, Shoichi
    Oka, Masaaki
    HEPATO-GASTROENTEROLOGY, 2010, 57 (97) : 172 - 177
  • [45] Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment
    Shitara, Kohei
    Yatabe, Yasushi
    Matsuo, Keitaro
    Sugano, Masato
    Kondo, Chihiro
    Takahari, Daisuke
    Ura, Takashi
    Tajika, Masahiro
    Ito, Seiji
    Muro, Kei
    GASTRIC CANCER, 2013, 16 (02) : 261 - 267
  • [46] Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment
    Kohei Shitara
    Yasushi Yatabe
    Keitaro Matsuo
    Masato Sugano
    Chihiro Kondo
    Daisuke Takahari
    Takashi Ura
    Masahiro Tajika
    Seiji Ito
    Kei Muro
    Gastric Cancer, 2013, 16 : 261 - 267
  • [47] Application of Circulating Tumor Cells and Circulating Free DNA from Peripheral Blood in the Prognosis of Advanced Gastric Cancer
    Yu, Pengjie
    Zhu, Shengmao
    Luo, Yushuang
    Li, Ganggang
    Pu, Yongqiang
    Cai, Baojia
    Zhang, Chengwu
    JOURNAL OF ONCOLOGY, 2022, 2022
  • [48] A new score based on biomarker values to predict the prognosis of locally advanced cervical cancer
    Maulard, Amandine
    Chargari, Cyrus
    Faron, Matthieu
    Alwohaibi, Asim
    Leary, Alexandra
    Pautier, Patricia
    Genestie, Catherine
    Morice, Philippe
    Gouy, Sebastien
    GYNECOLOGIC ONCOLOGY, 2020, 159 (02) : 534 - 538
  • [49] Neoadjuvant Chemotherapy in Asian Patients With Locally Advanced Gastric Cancer
    Tong, Xie
    Zhi, Peng
    Lin, Shen
    JOURNAL OF GASTRIC CANCER, 2023, 23 (01) : 182 - 193
  • [50] Indications for neoadjuvant treatment based on risk factors for poor prognosis before and after neoadjuvant chemotherapy alone in patients with locally advanced rectal cancer
    Ogura, Atsushi
    Uehara, Kay
    Aiba, Toshisada
    Sando, Masanori
    Tanaka, Aya
    Ohara, Noriaki
    Murata, Yuki
    Sato, Yusuke
    Hattori, Norifumi
    Nakayama, Goro
    Ebata, Tomoki
    Kodera, Yasuhiro
    Nagino, Masato
    EJSO, 2021, 47 (05): : 1005 - 1011